SLC5A2 and metabolic dysfunction-associated steatotic liver disease: Our study adds to the recent research investigating the role of empagliflozin; an SGLT-2 inhibitor recently reported to exert glycemic as well as pleiotropic effects on the progression of NAFLD and its symptoms.